{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:38:19Z","timestamp":1794472699882,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>New evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention have been realized in the recent years. An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PubMed, Cochrane and Science Direct data bases were utilized, RCTs evaluating dual antiplatelet vs mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack within &lt;\u200972\u2009h from ictus were searched up to July 2019. Risk ratio at 95% confidence intervals were calculated to evaluate stroke recurrence, cardiac events and mortality, and major bleeding.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen randomized controlled trials with a population of 28, 032 patients were pooled into a meta-analysis. Dual antiplatelet therapy was significantly superior over mono antiplatelet therapy in the reduction of stroke (RR 0.75, 95% CI:0.68\u20130.83, <jats:italic>p<\/jats:italic> value&lt;\u20090.00001) and composite events namely cardiovascular morbidity and mortality (0.73 95% CI: 0.65\u20130.82, <jats:italic>p<\/jats:italic> value &lt;\u20090.00001), while bleeding events were noted to be not significant (1.22 95% CI: 0.87\u20131.70, <jats:italic>p<\/jats:italic> value\u2009=\u20090.25).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In acute non-cardioembolic ischemic strokes or those who have suffered a transient ischemic attack, dual antiplatelet therapy was associated with efficacy in stroke recurrence and composite cardiac events, with a non-significant risk of major bleeding.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-020-01808-y","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:47:12Z","timestamp":1591195632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["RETRACTED ARTICLE: Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-0657","authenticated-orcid":false,"given":"Christessa Emille Que","family":"Albay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick Gavril D.","family":"Leyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federick C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"1808_CR1","unstructured":"Johns Hopkins Medicine \u201cTypes of Strokes\u201d. <https:\/\/www.hopkinsmedicine.org\/neurology_neurosurgery\/centers_clinics\/cerebrovascular\/stroke\/stroke_types_risk.html> (Accessed 20 Aug 2019)."},{"key":"1808_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012652","volume":"8","author":"J Aoki","year":"2019","unstructured":"Aoki J, Yasuyuki I, Takao U, et al. Acute aspirin plus Cilostazol dual therapy for Noncardioembolic stroke patients within 48 hours of symptom onset. J Am Heart Assoc. 2019;8:e012652. https:\/\/doi.org\/10.1161\/JAHA.119.012652.","journal-title":"J Am Heart Assoc"},{"key":"1808_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ahj.2010.05.017","volume":"160","author":"Y Wang","year":"2010","unstructured":"Wang Y, Johnston SC, CHANCE Investigators. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J. 2010;160:380\u20136.","journal-title":"Am Heart J"},{"key":"1808_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ijs.12129","volume":"8","author":"SC Johnston","year":"2013","unstructured":"Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013;8:479\u201383.","journal-title":"Int J Stroke"},{"issue":"6","key":"1808_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","volume":"18","author":"K Toyoda","year":"2019","unstructured":"Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2019;18(6):539\u201348.","journal-title":"Lancet Neurol"},{"key":"1808_CR6","doi-asserted-by":"crossref","unstructured":"Daniel H, Spence JD. Antiplatelet therapy in ischemic stroke and transient ischemic attack. An Overview of Major Trials and Meta-Analyses. J Am Heart Assoc. 2019;50:773\u20138.","DOI":"10.1161\/STROKEAHA.118.023954"},{"issue":"suppl 2","key":"1808_CR7","doi-asserted-by":"publisher","first-page":"e89S","DOI":"10.1378\/chest.11-2293","volume":"141","author":"JW Eikelboom","year":"2012","unstructured":"Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e89S\u2013119S.","journal-title":"Chest"},{"key":"1808_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1517\/13543784.16.2.225","volume":"16","author":"US Tantry","year":"2007","unstructured":"Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs. 2007;16:225\u20139. https:\/\/doi.org\/10.1517\/13543784.16.2.225.","journal-title":"Expert Opin Investig Drugs"},{"key":"1808_CR9","doi-asserted-by":"publisher","first-page":"k5108","DOI":"10.1136\/bmj.k5108","volume":"363","author":"Q Hao","year":"2018","unstructured":"Hao Q, Tampi M, O\u2019Donnell M, Foroutan F, Siemieniuk RAC, Guyatt G. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. BMJ. 2018;363:k5108.","journal-title":"BMJ"},{"key":"1808_CR10","unstructured":"American College of Cardiology \u201cGlobal Utilization of Streptokinase and TPA for Occluded Arteries\u201d < https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2010\/02\/23\/19\/06\/gusto-iib> (Accessed 28 Aug 2019)."},{"key":"1808_CR11","unstructured":"Modified Rankin Score (mRS) < https:\/\/manual.jointcommission.org\/releases\/TJC2018A\/DataElem0569.html> (Accessed 28 Aug 2019)."},{"key":"1808_CR12","unstructured":"NIH Stroke Scale International NIHSS <https:\/\/secure.trainingcampus.net\/uas\/modules\/trees\/windex.aspx?rx=nihss-english.trainingcampus.net > (Accessed 28 Aug 2019)."},{"key":"1808_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","volume":"24","author":"H Adams","year":"1993","unstructured":"Adams H, Bendixen B, Kapelle J, et al. Classification of subtype of acute ischemic stroke definition for use in a multicenter clinical trial. Stroke. 1993;24:35\u20131.","journal-title":"Stroke"},{"key":"1808_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"S Johnston","year":"2016","unstructured":"Johnston S, Amarenco P, Albers G, et al. Ticagrelor vs aspirin in acute stroke or transient ischemic attack. NEMJ. 2016;375:35\u201343.","journal-title":"NEMJ"},{"key":"1808_CR15","unstructured":"Mims <www.mims.com\/philippines\/drug\/info\/> (Accessed 15 Oct 2019)."},{"key":"1808_CR16","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","volume":"111","author":"HS Markus","year":"2005","unstructured":"Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005;111:2233\u201340.","journal-title":"Circulation"},{"key":"1808_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1474-4422(10)70060-0","volume":"9","author":"KS Wong","year":"2010","unstructured":"Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:489\u201397.","journal-title":"Lancet Neurol"},{"key":"1808_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","volume":"369","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. Engl J Med. 2013;369:11\u20139.","journal-title":"Engl J Med"},{"key":"1808_CR19","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1161\/CIRCULATIONAHA.113.003187","volume":"128","author":"KS Wong","year":"2013","unstructured":"Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation. 2013;128:1656\u201366.","journal-title":"Circulation"},{"key":"1808_CR20","doi-asserted-by":"crossref","unstructured":"Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215\u201325.","DOI":"10.1056\/NEJMoa1800410"},{"key":"1808_CR21","volume-title":"A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients","author":"J Kaye","year":"1989","unstructured":"Kaye J. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Bracknell: Boehringer-Ingelheim; 1989."},{"key":"1808_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","volume":"143","author":"HC Diener","year":"1996","unstructured":"Diener HC, Cunha L, Forbes C, et al. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1\u201313.","journal-title":"J Neurol Sci"},{"key":"1808_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","volume":"364","author":"HC Diener","year":"2004","unstructured":"Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH):randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331\u20137.","journal-title":"Lancet"},{"key":"1808_CR24","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706\u201317.","journal-title":"N Engl J Med"},{"key":"1808_CR25","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","volume":"367","author":"PH Halkes","year":"2006","unstructured":"Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665\u201373.","journal-title":"Lancet"},{"key":"1808_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","volume":"6","author":"J Kennedy","year":"2007","unstructured":"Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER):a randomised controlled pilot trial. Lancet Neurol. 2007;6:961\u20139.","journal-title":"Lancet Neurol"},{"key":"1808_CR27","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/STROKEAHA.109.564906","volume":"41","author":"PM Bath","year":"2010","unstructured":"Bath PM, Cotton D, Martin RH, et al. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010;41:732\u20138.","journal-title":"Stroke"},{"key":"1808_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1474-4422(09)70361-8","volume":"9","author":"R Dengler","year":"2010","unstructured":"Dengler R, Diener HC, Schwartz A, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:159\u201366.","journal-title":"Lancet Neurol"},{"key":"1808_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2011.09.038","volume":"313","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Tsuruta S, Uchiyama S. Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci. 2012;313:22\u20136.","journal-title":"J Neurol Sci"},{"key":"1808_CR30","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/STROKEAHA.115.012293","volume":"47","author":"KS Hong","year":"2016","unstructured":"Hong KS, Lee SH, Kim EG, et al. Recurrent ischemic lesions after acute Atherothrombotic stroke: Clopidogrel plus aspirin versus aspirin alone. Stroke. 2016;47:2323\u201330.","journal-title":"Stroke"}],"updated-by":[{"DOI":"10.1186\/s12883-020-02025-3","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"record-id":"24859"},{"DOI":"10.1186\/s12883-020-02025-3","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01808-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:24:12Z","timestamp":1628551452000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01808-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1808"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01808-y","relation":{"retraction":[{"id-type":"doi","id":"10.1186\/s12883-020-02025-3","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"10 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Clarification","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor's Note: Concerns have been raised about the data reported in this article. This is currently being investigated. Further editorial action may be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail: https:\/\/doi.org\/10.1186\/s12883-020-02025-3","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The investigators declare the we have no competing interests, individually for each of the authors present and as a group. Additionally, to the best of our knowledge, the named authors have no conflict of interest, financial or otherwise.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}